OS Therapies (NYSEAMERICAN:OSTX) Receives “Buy” Rating from D. Boral Capital

OS Therapies (NYSEAMERICAN:OSTX)‘s stock had its “buy” rating reaffirmed by investment analysts at D. Boral Capital in a note issued to investors on Monday,Benzinga reports. They currently have a $20.00 price objective on the stock.

A number of other research firms have also weighed in on OSTX. Lake Street Capital reduced their target price on OS Therapies from $18.00 to $17.00 and set a “buy” rating for the company in a report on Tuesday, November 18th. Zacks Research upgraded shares of OS Therapies from a “strong sell” rating to a “hold” rating in a research report on Tuesday, November 11th. Three equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $17.33.

OS Therapies Price Performance

NYSEAMERICAN:OSTX opened at $1.34 on Monday. OS Therapies has a 1 year low of $1.12 and a 1 year high of $7.00. The stock’s fifty day moving average price is $1.73 and its two-hundred day moving average price is $1.88. The company has a market cap of $47.18 million, a P/E ratio of -1.63 and a beta of -3.79.

OS Therapies (NYSEAMERICAN:OSTX) last announced its quarterly earnings results on Friday, November 14th. The company reported ($0.21) earnings per share for the quarter. On average, analysts expect that OS Therapies will post -0.64 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in OSTX. Susquehanna International Group LLP bought a new position in shares of OS Therapies in the third quarter worth approximately $29,000. Mercer Global Advisors Inc. ADV purchased a new position in shares of OS Therapies during the third quarter valued at about $40,000. Ground Swell Capital LLC purchased a new position in shares of OS Therapies during the 3rd quarter worth approximately $40,000. CM Management LLC raised its holdings in OS Therapies by 6.7% in the third quarter. CM Management LLC now owns 400,000 shares of the company’s stock worth $784,000 after purchasing an additional 25,000 shares in the last quarter. Finally, Bridgeway Capital Management LLC bought a new position in shares of OS Therapies in the 2nd quarter worth about $47,000.

About OS Therapies

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.